| |
|
|
| |
EVENT DETAILS |
You have a vision, great data & a well-executed pitch, but how do you get money & how do you get it from the right investor? Raising early-stage money for HealthTech & Life Science companies is never easy. How does it get done? From the lab to grants, or just straight to seed & Series A? On your way into the office, join us at JLABS @ NYC for coffee & a conversation on the subtle tips & tricks of raising seed funds from early stage life science venture capital funds. Topics will include: A Keynote presentation with Michelle Hartz | Golden Seeds Preparing to raise funds Pre-qualifying a fund Securing an introduction Questions you should ask Maintaining momentum Don't miss this unique insider's look at raising life science capital. Gain the knowledge to improve your odds for funding success. Bring your questions to this interactive session!
Featured Keynote Presentation: Michelle Hartz | Co-Chair , Golden Seeds read bio
Speakers: Tom Brennan | Venture Partner, Arch Venture Partners read bio Christine Borowski | Entrepreneur-in-Residence, Apple Tree Partners read bio Michelle Hartz | Co-Chair , Golden Seeds read bio V. Kadir Kadhiresan | Vice President, Venture Investments, Johnson & Johnson Development Corporation read bio Kate Merton | Head of JLABS @ NYC, Johnson & Johnson Innovation, JLABS read bio Agenda:` 09:00 AM | Registration & Networking Breakfast 09:30 AM | Keynote Presentation with Michelle Hartz from Golden Seeds 09:45 AM | Panel Disucssion 10:15 AM | Q&A 10:30 AM | Program Close Fees: Presentation & Breakfast $25 | Friends & Neighbors Includes Keynote presentation, panel,, Q&A, & refreshments. All attendees must pay this fee. Pre-registration to attend the presentation, Q&A, & networking will remain open until noon on May 14th (or sold out). Location: New York Genome Center 101 6th Ave New York, New York 10280 Participating Representatives: Michelle Hartz | Co-Chair , Golden Seeds Michelle Hartz is the co-chair of health care sector investments at Golden Seeds, one of the largest angel groups in the US. In this role, she is deeply immersed in screening, analyzing & helping to shepherd Golden Seeds investment opportunities in health tech, bio/pharma, diagnostics & medical devices. Golden Seeds, one of the nation's largest & most active angel investment groups in the US, focuses on funding young companies in which women play a powerful role. Our investment thesis rests on extensive research that concludes that gender diverse teams produce better return on equity. By seeking companies where women hold leadership positions & own substantial equity, we are funding companies that are likely to have diverse perspectives that will contribute to ultimate success. Since 2005, more than 275 Golden Seeds members along with our venture funds have invested over $90 million in more than 85 companies across the country. Michelle is also the founder of Hartz Consulting, a business advisory firm that specializes in working with companies that need expertise in the public policy & regulatory arenas. She is also an advisor to young companies & entrepreneurs as they navigate through policy issues that impact their businesses. Over the course of her career, Michelle has been an entrepreneur who founded three successful businesses; a senior corporate executive at major companies; a strategic business advisor to the leadership of the Fortune Global 500, public & private companies, venture capital & private equity firms; a private company board member; an advisor & investor in early stage companies, & co-founder of a pioneering biotechnology company. Michelle began her career with McKinsey & Company & in public accounting. Immediately prior to forming Hartz Consulting, in 2001, she was a managing director of Powell Tate, which she joined at its inception in 1991. Earlier in her career, she was a senior vice president at Burson-Marsteller, where she was responsible for its health care practice in Washington, D.C., & at the genesis of Bethesda Research Laboratories, a leading biotechnology company that had a successful exit in the earliest years of the biotechnology gold rush. Michelle is a Phi Beta Kappa graduate of the University of California at Los Angeles, where she earned an M.B.A., M.A., & B.A. Tom Brennan | Venture Partner, ARCH Venture Partners Tom Brennan joined ARCH in 2008 as a Venture Partner. He has special focus on ARCH activities at Sandia National Laboratories & Los Alamos National Laboratory, & the Life Sciences Accelerator in New York. During his first year with ARCH, he served as an Entrepreneur in Residence at Sandia National Laboratories (SNL), a position supported by a Department of Energy grant awarded to ARCH early in 2008. Mr. Brennan began his career as a member of the technical staff at AT&T Bell Labs, then joined SNL in 1986 where he became a senior member of the technical staff focused on the material growth of III-V semiconductor materials & devices. Mr. Brennan's work included the growth of some of the first vertical cavity surface-emitting laser' (VCSEL) material at SNL & in the U.S., & the development of new & unique VCSEL manufacturing techniques. In 1994, Mr. Brennan & a colleague from SNL collaborated with ARCH Managing Directors, Clint Bybee & Keith Crandell, to license the VCSEL technology from SNL & co-founded MicroOptical Devices (MODE). Mr. Brennan was Co-President of MODE through December 1997 when EMCORE Corp. acquired the firm & established a new business unit called EMCORE Photovoltaics, which Mr. Brennan started-up & led as its General Manager. In 2001, Mr. Brennan was named President & CEO of Zia Laser, a spin-out from the Center for High Technology Materials at the University of New Mexico, which developed quantum dot laser diodes. He also served as Chairman of Medical Lighting Solutions, which uses solid state lighting to treat disease. Mr. Brennan holds an A.S. in Chemistry from the Florida Institute of Technology, a B.S. in Biochemistry from Monmouth College, & an M.S. in Material Science from Steven's Institute of Technology. He has published more than 120 articles & holds twelve patents issued & pending. Christine Borowski | Entrepreneur-in-Residence, Apple Tree Partners Christine Borowski joined Apple Tree Partners in 2017 as an Entrepreneur-in-Residence focused on identifying & advancing early-stage translational medicine projects with high potential to general novel therapeutics. Prior to joining ATP, Christine held editorial positions at several scientific research journals, most recently Chief Editor of the leading translational research journal Nature Medicine. Christine holds a B.S. in Biology from the University of Kentucky, & a Ph.D. in immunology from Harvard University. Her doctoral work in the laboratory of Harald von Boehmer focused on the development of conventional T lymphocytes. During her postdoctoral work in Albert Bendelac's lab at the University of Chicago, Christine studied the differentiation of natural killer T cells. V. Kadir Kadhiresan, PhD | Vice President, Venture Investments, Johnson & Johnson Development Corporation Dr. Kadhiresan has more than a decade of operational experience in various functional roles including research, product development, & business development. Before joining JJDC, as head of Business Development at Guidant, now Boston Scientific, Dr. Kadhiresan led several transactions to access novel medical device technologies with venture investments, M&As, licensing & joint ventures. Prior to entering business development, he led the research & development of multiple early-stage technologies & products in cardiac rhythm management & heart failure. Dr. Kadhiresan was instrumental in the development of the cardiac resynchronization therapy for heart failure, now a multi-billion dollar worldwide market. At Heart Rhythm Technologies, a subsidiary of Guidant, he led the development of an ablation technology for treatment of atrial fibrillation & raised venture financing for the project. In addition, Dr. Kadhiresan is an inventor on more than 40 patents & has published several articles in peer-reviewed journals. Dr. Kadhiresan received a PhD & Master of Science in Biomedical Engineering from the University of Michigan, Ann Arbor, a Master of Business Administration from the Kellogg School of Management at Northwestern University, & a Bachelor of Science in Electrical Engineering from the National Institute of Technology (REC), Trichy, India.
Kate Merton Ph.D.| Head of JLABS @ NYC, Johnson & Johnson Innovation, JLABS As Head of Johnson & Johnson Innovation, JLABS in New York, Kate is responsible for external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence, educational programming & P&L. She catalyzes & supports the translation of science & technology into valuable solutions for patients & consumers across the pharmaceutical, medical device, consumer & healthtech sectors. Kate joins JLABS with 15 years of experience working across the Healthcare industry, starting in R&D before moving onto roles in Marketing, Business Development, External Alliances, Medical Affairs, Health Outcomes & most recently Disruptive Innovation. During her career Kate has been part of teams that have discovered new drugs, worked to develop & gain approval for blockbuster diabetes products & is passionate about being part of the future of healthcare where science intersects with the rapid advancements in health care technology Kate holds an undergraduate degree in Pharmacology & Toxicology from King's College London, & a PhD in Pharmacology & Toxicology from University of California, Irvine Medical School. She received her MBA from the Fuqua School of Business at Duke University.
|
|
|
|
|
|
